Plasma-Based Tumor Mutational Burden (Btmb) As Predictor For Survival In Phase Iii Eagle Study: Durvalumab (D) +/- Tremelimumab (T) Versus Chemotherapy (Ct) In Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M Hnscc) After Platinum Failure.

Weimin Li,Sophie Wildsmith,Jiabu Ye,Han Si, Nassim Morsli,Philip He,Jagdish Shetty,Alejandro Javier Yovine,Nicholas Holoweckyj,Rajiv Raja, Katia Real,Paul Scorer,Todd Hembrough,Jill Walker,Qu Zhang,Ricard Mesia,Robert I. Haddad,Lisa F. Licitra,Robert L. Ferris

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 29|浏览7

暂无评分

摘要

6511Background: In NSCLC, bTMB assessed from circulating tumor DNA shows promise as a predictive survival biomarker for immunotherapy, but its value in R/M HNSCC is uncertain. We evaluated bTMB as ...

查看译文

关键词

Durvalumab,Head and neck squamous-cell carcinoma,Tremelimumab,Biomarker (medicine),Immunotherapy,Chemotherapy,Cancer research,Medicine,Circulating tumor DNA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要